These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 12722024

  • 1. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D, Lahn M.
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [Abstract] [Full Text] [Related]

  • 2. Antisense strategies targeting protein kinase C: preclinical and clinical development.
    Tortora G, Ciardiello F.
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):26-31. PubMed ID: 12917818
    [Abstract] [Full Text] [Related]

  • 3. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6086-93. PubMed ID: 15447994
    [Abstract] [Full Text] [Related]

  • 4. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E.
    Clin Cancer Res; 2002 Aug 15; 8(8):2530-5. PubMed ID: 12171880
    [Abstract] [Full Text] [Related]

  • 5. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
    Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI.
    Cancer; 2004 Jan 15; 100(2):321-6. PubMed ID: 14716767
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.
    Curr Opin Mol Ther; 1999 Jun 15; 1(3):372-85. PubMed ID: 11713802
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
    Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D.
    Cancer Res; 1996 Aug 01; 56(15):3499-507. PubMed ID: 8758918
    [Abstract] [Full Text] [Related]

  • 9. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A.
    Mol Med Today; 1997 Aug 01; 3(8):324. PubMed ID: 9269683
    [No Abstract] [Full Text] [Related]

  • 10. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
    Geiger T, Müller M, Dean NM, Fabbro D.
    Anticancer Drug Des; 1998 Jan 01; 13(1):35-45. PubMed ID: 9474241
    [Abstract] [Full Text] [Related]

  • 11. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
    Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AL, Holmlund JT, McIntosh LW, Geary RS, Eisenhauer EA.
    Clin Cancer Res; 2002 Jul 01; 8(7):2188-92. PubMed ID: 12114419
    [Abstract] [Full Text] [Related]

  • 12. Antisense therapy in oncology: new hope for an old idea?
    Tamm I, Dörken B, Hartmann G.
    Lancet; 2001 Aug 11; 358(9280):489-97. PubMed ID: 11513935
    [Abstract] [Full Text] [Related]

  • 13. Antisense oligonucleotides in lung cancer.
    Pujol JL, Jacot W.
    Suppl Tumori; 2002 Aug 11; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract] [Full Text] [Related]

  • 14. ISIS-3521. Isis Pharmaceuticals.
    Li K, Zhang J.
    Curr Opin Investig Drugs; 2001 Oct 11; 2(10):1454-61. PubMed ID: 11890365
    [Abstract] [Full Text] [Related]

  • 15. The role of protein kinase C-alpha in malignancies of the nervous system and implications for the clinical development of the specific PKC-alpha inhibitor aprinocarsen (Review).
    Lahn MM, Sundell KL, Paterson BM.
    Oncol Rep; 2004 Feb 11; 11(2):515-22. PubMed ID: 14719093
    [Abstract] [Full Text] [Related]

  • 16. The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen.
    Hanauske AR, Sundell K, Lahn M.
    Curr Pharm Des; 2004 Feb 11; 10(16):1923-36. PubMed ID: 15180529
    [Abstract] [Full Text] [Related]

  • 17. Protein kinase C alpha expression in breast and ovarian cancer.
    Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF.
    Oncology; 2004 Feb 11; 67(1):1-10. PubMed ID: 15459489
    [Abstract] [Full Text] [Related]

  • 18. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
    Holmlund JT.
    Ann N Y Acad Sci; 2003 Dec 11; 1002():244-51. PubMed ID: 14751839
    [Abstract] [Full Text] [Related]

  • 19. Protein kinase C as a target for cancer therapy.
    Glazer RI.
    Antisense Nucleic Acid Drug Dev; 1997 Jun 11; 7(3):235-8. PubMed ID: 9212917
    [No Abstract] [Full Text] [Related]

  • 20. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA, Ratain MJ.
    Clin Cancer Res; 2002 Apr 11; 8(4):1042-8. PubMed ID: 11948111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.